Clinical Trial Update: Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of testosterone and olaparib in castration-resistant prostate cancer has completed, with results posted in May 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Olaparib (Olaparib)
• TESTOSTERONE (testosterone)

Snippet

Sponsor: University of Washington | Conditions: Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2022-05-18